 | | Fosamprenavir (Lexiva, Telzir) |  | | Published
October 30, 2003; Updated
May 17, 2012 | Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-03-08 | | | Selected References | | 3. | Press release: Vertex Reports Preliminary 48-Week Data from Phase III Study of 433908, an Investigational HIV Protease Inhibitor. 7/24/03. http://www.vpharm.com/Pressreleases2003/pr072403.html | |
| 4. | DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. The Context Study: Efficacy and Safety of GW433908/RTV in PI-experienced Subjects with Virological Failure (24 Week Results). 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003. Abstract 178. | |
|
|
|
